---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-030356"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2023-03-09T23:59:59+00:00"
generated_at: "2026-06-18T07:13:16.157422+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NRx Pharmaceuticals closes $2.9M registered direct offering of common stock and warrants

## Summary
- Gross proceeds of ~$2.9M from sale of 3,766,666 shares and 3,766,666 warrants at $0.75 per unit.
- All investors are existing holders; shares restricted from transfer for 6 months.
- Warrants exercisable at $0.75 starting 6 months after issuance, expiring in 5 years.
- Proceeds to fund working capital and initiate national treatment protocol for NRX-101 for bipolar depression with suicidal risk.
- Offering closed on March 9, 2023 under existing effective S-3 registration statement.

## SEC filing metadata
- accession: 0001104659-23-030356
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2023-03-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000110465923030356/0001104659-23-030356-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000110465923030356/tm238149d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-030356
- JSON: https://secwatch.observer/filing/0001104659-23-030356.json
- Plain text: https://secwatch.observer/filing/0001104659-23-030356.txt

## Key facts
- Material Agreements
  NRX Pharmaceuticals, Inc. entered into Securities Purchase Agreement with the purchasers listed on the signature page thereto (the "Investors") valued at $0.75 per share (effective 2023-03-08).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the purchasers listed on the signature page thereto (the "Investors")
  - Value: $0.75 per share
  - Effective: 2023-03-08
  source text: On March 8, 2023, NRx Pharmaceuticals, Inc. (the "Company," "us" or "we") entered into a securities purchase agreement (the "Securities Purchase Agreement") with the purchasers listed on the signature page thereto (the "Investors"), providing for the issuance and sale of 3,766,666 shares of the Company's common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000110465923030356/0001104659-23-030356-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.